The Parkinsonian Syndrome and its Dopamine Correlates
The urinary excretion of free dopamine in 37 untreated parkinsonian patients correlated negatively with the severity of rigidity and akinesia (p<0.025) and with total neurologic deficit (p<0.05). In a parallel study of psychiatric patients, those with the lowest levels of urinary free dopamine before treatment were the most vul nerable to, and developed the most severe, secondary parkinsonian rigidity (p<0.005), akinesia (p<0.05), and total deficit (p<0.01) when they were subsequently treated for two weeks with trifluoperazine. In neither study was there a significant correlation between free urinary dopamine and tremor.
These studies directly associate the level of free dopamine in the urine with the severity of the parkinsonian syndrome. Therefore, although many peripheral sources contribute to urinary free dopamine, a small decrease in the level may actually reflect the severity of the disturbance of central dopamine metabolism and the known deficiency of dopamine in the neurons of the parkinsonian brain.
KeywordsPsychiatric Patient Parkinsonian Patient Neurologic Deficit Score Extrapyramidal Sign Parkinsonian Sign
Unable to display preview. Download preview PDF.
- Barbeau, A. (1969a). Parkinson’s disease as a systemic disorder. In Third Symposium on Parkinson’s Disease (Gillingham, F.J. and Donaldson, I.M.L., Eds.) pp. 66–73. E.S. Livingstone Ltd., Edinburgh and London.Google Scholar
- Barbeau, A. (1969b). L-dopa therapy in Parkinson’s disease: A crit ical review of nine years’ experience. Can. Med. Assoc. J. 101 ,791–800.Google Scholar
- Barbeau, A., Sourkes, T.L. and Murphy, G.F. (1961b). Les catecholamines dans la maladie de Parkinson. In Monoamines et Systeme Neryeux CentraZ (de Ajuriaguerra, J., Ed.) pp. 247–262. Georg + Cie S.A., Geneva.Google Scholar
- Birkmayer, W. and Hornykiewicz, O. (1961). Der L-3,4-Dioxyphenylalanin (= Dopa) - Effekt bei der Parkinson - Akinese. Weiner Klin. Wochenschr. 73 ,787–788.Google Scholar
- Crane, G.E. (1974). Factors predisposing to drug-induced neurologic effects. In The Phenothiazines and Structurally Related Drugs (Forrest, I.S., Carr, C.J. and Usdin, E., Eds.) pp. 269–279. Raven Press, New York.Google Scholar
- Hornykiewicz, 0. (1971). Histochemistry, biochemistry, and pharmacology of brain catecholamines in extrapyramidal syndromes in man. In Monoamines Noyaux Gris Centraux et Syndrome de Parkinson (de Ajuriaguerra, J. and Gauthier, G., Eds.) pp. 143–157. Georg -I- Cie S.A., Geneva.Google Scholar
- Lloyd, K.G., Davidson, L. and Hornykiewicz, O. (1973). Metabolism of levodopa in the human brain. In Advances in Neurology. (Calne, D.B., Ed.) 3 ,pp. 173–188. Raven Press, New York.Google Scholar
- Stadlan, E.M., Duvoisin, R. and Yahr, M.D. (1965). The pathology of parkinsonism. In Proceedings of the Fifth International Congress of Neuropathology (Lüthy, F. and Bischoff, A., Eds.) pp. 569–571. International Congress Series No. 100, Excerpta Medica, Amsterdam.Google Scholar
- Strian, F., Micheler, E. and Benkert, O. (1972), Tremor inhibition in parkinson syndrome after apomorphine administration under L-dopa and decarboxylase inhibitor basic therapy. Pharmakopsych. Neuro-Psychopharmakol. 5 ,198–205.Google Scholar
- Yahr, M.D., Duvoisin, R.C., Hoehn, M.M., Schear, M.J. and Barrett, R.E. (1968). L-dopa - its clinical effects in parkinsonism. Trans. Amer. Neurol. Assoc. 93 ,56–63.Google Scholar